Irinotecan 40mg - Description , Uses , Prices , Side effects.

Irinotecan 40mg (Irinotecan)

Write feedback

composition: Irinotecan

Brand nameCamptoInternational trade nameCamptosarActive substanceIrinotecanStrength40mgCategoryAnti Cancer

Description of Campto 40mg (Irinotecan 40mg)

Campto 40mg (Irinotecan 40mg) is a camptothecin derivative that exerts antitumor activity against a variety of tumors.The active metabolite of Campto is SN-38 produced in the body by carboxylesterase .

Campto 40mg (Irinotecan 40mg) is used to cure cancers of the colon and rectum. It is usuallyadministering with other chemotherapy medicines in a combination chemotherapy.

Campto 40mg (Irinotecan 40mg) is a prescription drugs which is used under supervision by medical physician

Medical use /Indication of Campto 40mg (Irinotecan 40mg)

Campto 40mg (Irinotecan 40mg) is mainly used for the treatment in patients with metastatic colon or rectal cancer.

Mechanism of Action Campto 40mg (Irinotecan 40mg)

Camptothecin is a derivative of irinotecan which interact particularly with the enzyme topoisomerase I, which relieves torsional strain in DNA by activating reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and inhibitsrelocation of these single-strand breaks. The cytotoxicity of Irinotecan is because of double-strand DNA injury produced during DNA combination when multiplication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either Irinotecan or SN-38. Mammalian cells cannot expertly repair these double strand breaks.

Absorption of Campto 40mg (Irinotecan 40mg)

Campto 40mg (Irinotecan 40mg) has time to Peak Plasma Concentration of Campto 40mg (Irinotecan 40mg) is 1660 ng/mL; SN-38 26.3 ng/mL

Distribution of Campto 40mg (Irinotecan 40mg)

Campto 40mg (Irinotecan 40mg) has Protein Bound: 30-68%; SN-38 95% and Vd: 110-234 L/m²

Metabolism of Campto 40mg (Irinotecan 40mg)

Campto 40mg (Irinotecan 40mg) is mainly metabolized in hepatic, to SN-38; SN-38 is further metabolized by UGT1A1 and metabolites are metabolized to SN-38

Excretion of Campto 40mg (Irinotecan 40mg)

Excretion of Campto 40mg (Irinotecan 40mg) through urine, feces
Half-Life of Campto 40mg (Irinotecan 40mg): 6-12 hr; SN-38 10-20 hr

Side effects of Campto 40mg (Irinotecan 40mg)

Common side effects of Campto 40mg (Irinotecan 40mg) :

Anxiety, Black, tarry stools, Changes in skin colour, Bruising, Chest pain, Decrease appetite, Confusion, Constricted pupils, Hoarseness, Dark urine , Hair loss, Mouth ulcers, Tummy pain.

Serious side effects of Campto 40mg (Irinotecan 40mg) :

Decreased amount of urine, Troubled breathing, Hives , Rapid weight gain, Constipation, Liver changes, Increased blood pressure, Swelling around the drip site, Skin rash, Dizziness, Blood clots.

Precautions of Campto 40mg (Irinotecan 40mg)

Drug Campto 40mg (Irinotecan 40mg) is exposed to photodegradation, specifically in neutral & alkaline solutions
When treatment will cause Hyperbilirubinemia, elderly, receiving radiation therapy, abdominal/pelvic radiation history
Not for use in concomitant with a regimen of 5-FU/LV administered for 4-5 consecutive days every 4 weeks outside of a clinical study
While on Campto 40mg (Irinotecan 40mg) treatment interstitial pulmonary disease (IPD)-like events, contains fatalities, have been resulted (in combination and as monotherapy) for treatment of colorectal cancer and other advanced solid tumors
Risk of both early and late forms of diarrhea will occurs on treatment with Campto 40mg (Irinotecan 40mg)
Risk of serious myelosuppression; manage febrile neutropenia immediately with antibiotic support; discontinue therapy and decrease subsequent doses if necessary

Drug interaction of Campto 40mg (Irinotecan 40mg)

When interaction of Campto 40mg (Irinotecan 40mg)with 5-fluorouracil and leucovorin (LV), the disposition of irinotecan was not substantially altered.
Co administration of Campto 40mg (Irinotecan 40mg)with strong CYP34A inducers do not administer unless there are no therapeutic alternatives
When concomitant use of Campto 40mg (Irinotecan 40mg) with strong CYP34A inhibitors may increase systemic exposure to irinotecan or SN-38

Contraindication of Campto 40mg (Irinotecan 40mg)

Campto 40mg (Irinotecan 40mg) contraindicated in patients with known hypersensitivity to the drug or its excipients

Pregnancy of Campto 40mg (Irinotecan 40mg)

Pregnancy category is D

The drug Campto 40mg (Irinotecan 40mg) may causes risk to fetus when administered to pregnant women. Advice the women about the potential hazard to the fetus

Lactation of Campto 40mg (Irinotecan 40mg)

The drug Campto 40mg (Irinotecan 40mg) has no data on the excretion into human milk. Advice the breastfeed mother potential risk to the infants. So, discontinue nursing when getting treatment with Campto.

Dosage of Campto 40mg (Irinotecan 40mg)

Colorectal cancer :

Monotherapy dosage :

Premediate the patients with antiemetic agents

For experience cholinergic symptoms in patient’s atropine treatment should be considered

Dose 1: 125mg/m2 IV infusion over 90 minutes on days 1,8,15,22, then 2 weeks off then repeat administrated weekly Dose 2: 350mg/sq. meter IV Infusion over 30-90 minutes q3weeks administrated once every 3 weeks.

Combination therapy :

Premediate the patients with antiemetic agents

For experience cholinergic symptoms in patient’s atropine treatment should be considered

Dose 1: 180mg/m2 IV infusion over 30-90 minutes once on days 1,15, and 29, then followed by infusion with leucovorin and 5- fluorouracil; next cycle begins on day 43

Dose 2: 125mg/sq. meter on days 1,8,15 and 22 IV Infusion over 90 minutes then followed by bolus doses of leucovorin and 5-fluorouracil